http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0002861-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c588741b87e1d0442c1f6924f99a235d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb9dcaa09439c03f623c6b3c2b77d2d3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-90 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04 |
| filingDate | 1999-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d40343b966844a795a723008d7d86ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bf0cebae7ebcca8219b60bb866c2f35 |
| publicationDate | 2000-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0002861-A1 |
| titleOfInvention | A3 adenosine receptor antagonists |
| abstract | The present invention provides certain novel pyridine and dihydropyridine derivatives, pharmaceutical compositions comprising one or more of these derivatives, and a method of treating a mammal by selectively blocking an A3 adenosine receptor of the mammal by the administration of a pyridine or dihydropyridine derivative of the present invention. Thus, for example, the present invention provides the following pyridine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; wherein R2 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, and C1-C6 alkoxy C1-C6 alkyl; R3 is selected from the group consisting of C1-C6 alkoxy, C1-C6 alkylsulfanyl, hydroxy, C1-C6 alkoxy C1-C6 alkylsulfanyl, hydroxy C1-C6 alkylsulfanyl, and halo C1-C6 alkylsulfanyl, or R3 together with R4 forms a 3-7 membered heterocyclic ring containing O, N, or S; R4 is selected from the group consisting of C1-C6 alkyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylsulfanyl, C1-C6 alkylamino, C1-C6 alkylcarbonyl sulfanyl C1-C6 alkyl, aryl C2-C6 alkenyl, aryl C2-C6 alkynyl, formyl, and acetal; R5 is selected from the group consisting of C1-C6 alkyl, aryl C1-C6 alkyl, hydroxy C1-C6 alkyl, and halo C1-C6 alkyl; and R6 is selected from the group consisting of aryl, C3-C7 cycloalkyl, and haloaryl; wherein said aryl is a phenyl or naphthyl. The compounds of the present invention can be used for inhibiting the binding of ligands to an adenosine receptor of a substrate. The compounds of the present invention can be used for characterizing an adenosine receptor in a substrate. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1706412-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1706412-A1 |
| priorityDate | 1998-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 705.